Shares of Alnylam Pharmaceuticals (ALNY) took a sharp dive during Monday's trading session, plummeting 5.03% following news that Goldman Sachs had removed the company from its prestigious US Conviction List. This unexpected development has sent ripples through the biotech sector, causing investors to reassess their positions in the RNA interference therapeutics pioneer.

The removal from Goldman Sachs' Conviction List, which typically includes the investment bank's top stock picks, comes as part of the firm's monthly update. While the specific reasons for Alnylam's removal were not immediately clear, such actions often signal a shift in the bank's outlook on a company's near-term performance or valuation.

Despite this setback, it's worth noting that Alnylam has recently been recognized for successful drug launches in the biotech sector. However, the market's immediate reaction to Goldman Sachs' decision underscores the significant influence that major investment banks can have on stock performance, particularly in the volatile biotech industry. Investors will be closely watching for any further analyst commentary or company updates that might provide additional context for this sudden shift in sentiment.